PHS
GPCR icon

PFM Health Sciences’s Structure Therapeutics GPCR Stock Holding History

PFM Health Sciences’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.91M Sell
91,550
-34,833
-28% -$1.54M 0.42% 69
2026
Q1 		$6.09M Buy
126,383
+58,135
+85% +$3.98M 0.56% 57
2025
Q4 		$4.75M Sell
68,248
-46,825
-41% -$1.91M 0.47% 53
2025
Q3 		$3.22M Buy
115,073
+58,479
+103% +$1.16M 0.25% 59
2025
Q2 		$1.17M Buy
56,594
+16,194
+40% +$356K 0.1% 54
2025
Q1 		$699K Buy
+40,400
New +$990K 0.05% 62

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

PFM Health Sciences's GPCR Position: Q2 2026 in Review

PFM Health Sciences reduced its Structure Therapeutics (GPCR) stake by 28% in Q2 2026, selling an estimated $1.54M and leaving 91,550 shares worth $4.91M. The position accounts for 0.42% of the portfolio, ranked #69.

PFM Health Sciences first reported a position in GPCR in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.09M in Q1 2026. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • PFM Health Sciences held 91,550 shares of Structure Therapeutics worth $4.91M as of Q2 2026.
  • PFM Health Sciences sold 34,833 Structure Therapeutics shares in Q2 2026, an estimated $1.54M.
  • Structure Therapeutics made up 0.42% of PFM Health Sciences's portfolio in Q2 2026, its #69 holding.
  • PFM Health Sciences first reported a position in Structure Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • PFM Health Sciences's Structure Therapeutics position peaked at $6.09M in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.